Evaluation of efficacy of thiotropium bromide administration to chronic obstructive lung disease patients at Novosibirsk region

Abstract

A regional branch programme "Improvement of quality of life of COPD patients" had been developed and adopted at Novosibirsk region. Its content is financial support and organization of COPD treatment using thiotropium bromide.
The study involved 35 COPD patients, 31of them (28 males and 3 females) completed the treatment. The average age of participants was 53.2 ± 3.9 yrs. We assessed severity of clinical signs using a 3-point scale; spirometry parameters, physical tolerability in 6-minute walk test. We also calculated cost of therapy of COPD patients. The follow-up duration was 6 months. Results demonstrated a significant reduction in clinical severity of COPD, improvement in functional capacity during the treatment with Spiriva. The rate of seeking for aid, number of seek days and length of staying in a hospitals decreased. Medical expenses for COPD treatment increased when used Spiriva due to its high cost but with regards to a total expenditure (direct and indirect) the cost-efficacy was 32.7 %.